Theralase Technologies leads the way in light-activated cancer therapies
Deep Dive - Theralase Technologies Inc
Source: proactiveinvestors.com
Evaluable Patients News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Evaluable Patients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Evaluable Patients Today - Breaking & Trending Today
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company’s ADVANCED-1 Phase 1a, Phase 1b-expansio
Source: yahoo.com
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101...
Source: marketscreener.com
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients ...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -
Source: eagletribune.com
Aptose Reports Results for the Second Quarter 2023
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc...
Source: globenewswire.com